Short answer
Biogen (BIIB) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.03 (Creation of a Direct Financial Obligation), Item 7.01 (Regulation FD Disclosure). $2B unsecured term loan funds portion of Apellis acquisition consideration.
Biogen 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $2B unsecured term loan funds portion of Apellis acquisition consideration
- Tranche A: $1B due May 12, 2027; Tranche B: $1B due May 12, 2028
- Term SOFR margins of 0.750% for Tranche A and 0.750%-1.000% for Tranche B
- Quarterly maximum consolidated leverage ratio 3.75x, temporarily expandable to 4.25x for qualifying acquisitions
- Apellis CVRs offer up to $4 per CVR based on SYFOVRE sales milestones of $1.5B and $2B during 2027-2031
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Biogen completed its Apellis acquisition on May 14, 2026, making Apellis a wholly owned subsidiary without an Apellis shareholder vote
- 105.7 million shares tendered, representing approximately 82.4% of Apellis shares outstanding
- Transaction consideration: $41 per share plus one CVR worth up to $4 per share upon specified milestones
- Upfront purchase cost approximately $5.3 billion, excluding fees, expenses, and CVR payments
- Maximum CVR exposure estimated at approximately $582 million, increasing potential acquisition consideration if milestones are achieved
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 references Biogen’s May 14, 2026 press release announcing consummation of the Merger
- Merger completion may create or alter Biogen’s financial obligations, requiring review of Exhibit 99.1 for transaction terms
- No debt amount, interest rate, maturity, or borrowing purpose disclosed in the provided text
Item 7.01 · Regulation FD Disclosure
- Item 7.01 contains only standard Regulation FD filing language
- No substantive company disclosure or investor-actionable information provided
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biogen 8-K filings
Get the next BIIB 8-K as it lands
Follow BIIB for push alerts, or ask the research agent what this filing means.